These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Transjugular intrahepatic portosystemic shunt creation may be associated with hyperplastic hepatic nodular lesions in the long term: an analysis of 18 pediatric and young adult patients. Woerner AJ; Shin DS; Chick JFB; Koo KSH; Hsu EK; Tang ER; Monroe EJ Pediatr Radiol; 2021 Jul; 51(8):1348-1357. PubMed ID: 33783576 [TBL] [Abstract][Full Text] [Related]
4. Increase in hepatic arterial blood flow after transjugular intrahepatic portosystemic shunt creation and its potential predictive value of postprocedural encephalopathy and mortality. Patel NH; Sasadeusz KJ; Seshadri R; Chalasani N; Shah H; Johnson MS; Namyslowski J; Moresco KP; Trerotola SO J Vasc Interv Radiol; 2001 Nov; 12(11):1279-84. PubMed ID: 11698626 [TBL] [Abstract][Full Text] [Related]
14. Percutaneous transhepatic intrahepatic portosystemic shunt for variceal bleeding with chronic portal vein occlusion after splenectomy. Luo J; Li M; Zhang Y; Wang H; Huang M; Li Z; Chen J; Wu C; Qian J; Guan S; Jiang Z Eur Radiol; 2018 Sep; 28(9):3661-3668. PubMed ID: 29600476 [TBL] [Abstract][Full Text] [Related]
15. Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation. Gaba RC; Couture PM; Bui JT; Knuttinen MG; Walzer NM; Kallwitz ER; Berkes JL; Cotler SJ J Vasc Interv Radiol; 2013 Mar; 24(3):411-20, 420.e1-4; quiz 421. PubMed ID: 23312989 [TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes and Patency after Transjugular Intrahepatic Portosystemic Shunt Reduction for Overshunting Adverse Events. Shah RJ; Alqadi MM; Duvvuri M; Kim YJ; Tyagi R; Lokken RP; Gaba RC J Vasc Interv Radiol; 2022 Dec; 33(12):1507-1512. PubMed ID: 35964879 [TBL] [Abstract][Full Text] [Related]